» Articles » PMID: 25305447

MiR-132, MiR-15a and MiR-16 Synergistically Inhibit Pituitary Tumor Cell Proliferation, Invasion and Migration by Targeting Sox5

Overview
Journal Cancer Lett
Specialty Oncology
Date 2014 Oct 12
PMID 25305447
Citations 84
Authors
Affiliations
Soon will be listed here.
Abstract

MiR-132, miR-15a and miR-16 have been implicated in the pathogenesis of many types of cancer, including pituitary tumors. However, the molecular mechanism of these miRNAs in pituitary tumor growth and metastasis is still unclear. Here, we showed that miR-132 and miR-15a/16 were less expressed in pituitary tumor cell lines, as well as in invasive pituitary tumor tissues, compared to non-invasive tumor tissues. We described that overexpression of miR-132 and miR-15a/16 resulted in the suppression of pituitary tumor cell proliferation, migration and invasion, respectively, and also inhibits the expression of proteins involved in Epithelial to Mesenchymal Transition (EMT). Then, we show that these miRNAs synergistically target Sox5 in pituitary tumor. Moreover, we found that Sox5 overexpression partially rescued miR-132, miR-15a and miR-16-mediated inhibition of cell migration, invasion and cell growth. Finally, we confirmed that Sox5 was upregulated in invasive pituitary tumor tissues, compared to non-invasion tissues. In conclusion, our data indicate that miR-132 and miR-15a/16 act as tumor suppressor genes in pituitary tumor by directly targetting Sox5, and imply that these miRNAs have potential as therapeutic targets for invasive pituitary tumor.

Citing Articles

Long non-coding RNA-MIR181A1HG acts as an oncogene and contributes to invasion and metastasis in gastric cancer.

Zhang J, Wei X, Xie Y, Peng S, Yang P, Chen Y Oncogene. 2025; .

PMID: 40044982 DOI: 10.1038/s41388-025-03323-1.


A missense variant in the SOX5 gene (c.221C > T) is associated with intellectual disability.

Yang X, Gan Z, Guo X, Huang X, Liu J, Zheng Y Orphanet J Rare Dis. 2025; 20(1):50.

PMID: 39905544 PMC: 11796025. DOI: 10.1186/s13023-025-03548-z.


Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: Recent insights and potential clinical applications.

Hashemi M, Abolghasemi Fard A, Pakshad B, Asheghabadi P, Hosseinkhani A, Hosseini A Noncoding RNA Res. 2024; 11:1-21.

PMID: 39720352 PMC: 11665378. DOI: 10.1016/j.ncrna.2024.11.006.


Approaches based on natural products and miRNAs in pituitary adenomas: unveiling therapeutic intervention.

Aboregela A Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(1):69-88.

PMID: 39102032 DOI: 10.1007/s00210-024-03347-6.


Biological functions and therapeutic potential of SRY related high mobility group box 5 in human cancer.

Xue J, Xiang W, Cai M, Lv X Front Oncol. 2024; 14:1332148.

PMID: 38835366 PMC: 11148273. DOI: 10.3389/fonc.2024.1332148.